Kairos Pharma Ltd. (NYSE American: KAPA) presented interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. The data, disclosed by President and Chief Scientific Officer Neil Bhowmick, show a statistically significant improvement in median progression-free survival (PFS) for patients with metastatic castration-resistant prostate cancer (mCRPC) receiving ENV-105 in combination with apalutamide compared to apalutamide alone. Median PFS was 17.7 months versus two months, respectively (P=0.0008), a more than eight-fold extension of the time before disease progression.
The result matters because mCRPC remains a lethal stage of prostate cancer, and resistance to standard androgen receptor pathway inhibitors such as apalutamide inevitably emerges. ENV-105 is a first-in-class antibody targeting CD105, a protein that Kairos identifies as a key driver of resistance and relapse. By blocking CD105/BMP signaling, the drug is designed to interrupt resistance mechanisms and restore sensitivity to established therapies. Bhowmick said the findings support the company's hypothesis that targeting CD105 may achieve exactly that. If confirmed in larger trials, the approach could extend the benefit of existing hormonal treatments and delay the need for more toxic chemotherapy.
The Phase 2 trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group. This shift is important because enzalutamide is widely used before apalutamide in the treatment sequence, so demonstrating activity in that specific setting would address a major unmet need. ENV-105 is also being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer, suggesting a broader opportunity across tumor types. Previous preclinical research has shown that ENV-105 may enhance radiation sensitivity in prostate cancer models, further supporting its potential as a combination agent. For investors, the interim data provide a significant de-risking event for a clinical-stage company whose value hinges on ENV-105. The statistically significant PFS benefit, while from a small interim analysis, is a strong signal that the CD105 mechanism may translate into clinical benefit.
Kairos Pharma, based in Los Angeles, California, is focused on overcoming drug resistance and immune suppression in cancer through structural biology. The company's newsroom, available at https://ibn.fm/KAPA, provides the latest updates. The full press release can be viewed at https://ibn.fm/PIrky. TinyGems, a communications platform focused on small-cap and mid-cap companies, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, delivering wire solutions through InvestorWire and editorial syndication to 5,000+ outlets. Terms of use and disclaimers are available at https://www.TinyGems.com/Disclaimer.
